|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TABLE OF CONTENTS (Linked) |
|
|
|
|
|
Docket #
|
|
Title
|
|
|
|
|
|
|
|
|
|
2003D-0228
|
|
Draft Guidance for Industry
on Continuous Marketing Applications: Pilot 1 b Reviewable
Units for Fast Track Products Under PDUFA |
|
|
|
|
|
2003P-0274
|
|
In re Tier 1 initial Approval
Program |
|
|
|
|
|
2003P-0275
|
|
Reclassify Cyclosporine (CSA)
as Non-antibiotic Drug |
|
|
|
|
|
2003P-0276
|
|
Establish Interim Accetable
Levels for Acrylamide In Major Food Sources |
|
|
|
|
|
2003P-0277 |
|
Indicate to Potential Users
of a Drug by Means of Labelling Whether Any Product Had Used
Human Embryo or Material Derived From Human Embryos in Its
Development, Production or Testing |
|
|
CONTENTS |
|
|
1977N-0094A |
|
Internal analgesic, antipyretic
& antirheumatic drug |
|
|
|
|
|
|
|
BKG 2 |
|
Background Information
|
|
Vol #: |
|
1 |
|
|
|
|
|
2002H-0443 |
|
Civil Money Penalty Re: LaHaye
Ctr.for Advanced Eye Care |
|
|
|
|
|
|
|
CS 11 |
|
HFA-305 |
|
Vol #: |
|
1 |
|
|
|
|
|
MO 8 |
|
LaHaye Ceter for Advanced Eye
Care of Lafayette, D/B/A LaHaye Total Eye Care |
|
Vol #: |
|
1 |
|
|
|
|
|
MO 9 |
|
LaHaye Center for Advanced
Eye Care of Lafayette, D/B/A LaHaye Total Eye Care
|
|
Vol #: |
|
1 |
|
|
|
|
|
OR 9 |
|
HF-3 |
|
Vol #: |
|
1 |
|
|
|
|
|
2003D-0228 |
|
Draft Guidance for Industry
on Continuous Marketing Applications: Pilot 1 b Reviewable
Units for Fast Track Products Under PDUFA |
|
|
|
|
|
|
|
GDL 1
|
|
Guidance |
|
Vol #: |
|
1 |
|
|
|
|
|
2003N-0193 |
|
Ophthalmic Drug Products for
Over-the-Counter Human Use; Final Monograph; Technical Amendment
|
|
|
|
|
|
|
|
BKG 1 |
|
Background Information
|
|
Vol #: |
|
1 |
|
|
|
|
|
2003P-0274 |
|
In re Tier 1 initial Approval
Program |
|
|
|
|
|
|
|
ACK 1 |
|
HFA to Abigail Alliance and
the Washington Legal Foundation |
|
Vol #: |
|
1 |
|
|
|
|
|
CP 1 |
|
Abigail Alliance and the Washington
Legal Foundation |
|
Vol #: |
|
1 |
|
|
|
|
|
2003P-0275 |
|
Reclassify Cyclosporine (CSA)
as Non-antibiotic Drug |
|
|
|
|
|
|
|
ACK 1 |
|
HFA-305 |
|
Vol #: |
|
1 |
|
|
|
|
|
CP 1 |
|
Allergan Inc. |
|
Vol #: |
|
1 |
|
|
|
|
|
2003P-0276 |
|
Establish Interim Accetable
Levels for Acrylamide In Major Food Sources |
|
|
|
|
|
|
|
ACK 1 |
|
HFA-305 |
|
Vol #: |
|
1 |
|
|
|
|
|
CP 1 |
|
CSPI |
|
Vol #: |
|
1 |
|
|
|
|
|
2003P-0277 |
|
Indicate to Potential Users of a Drug by Means of Labelling
Whether Any Product Had Used Human Embryo or Material Derived
From Human Embryos
in Its Development, Production or Testing |
|
|
|
|
|
